FIELD: medicine.
SUBSTANCE: disclosed is a pharmaceutical composition for the treatment of depressive disorder with melancholic features, comprising an opioid antagonist with κ-activity where said opioid antagonist with κ-activity is nalmefene or a pharmaceutically acceptable salt thereof, and vortioxetine or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient.
EFFECT: technical result: high efficiency compared with use of nalmefene or vortioxetine separately.
1 cl, 2 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF TREATING OPIOID OVERDOSE | 2017 |
|
RU2769397C2 |
| NEUROGENESIS MEDIATED WITH 4-ACYLAMINOPYRIDINE DERIVATIVES | 2007 |
|
RU2451512C2 |
| USE OF MAVOGLURANT TO REDUCE ALCOHOL USE OR TO PREVENT RECURRENT ALCOHOL USE | 2018 |
|
RU2806869C2 |
| COMPOSITIONS CONTAINING VORTIOXETINE AND DONEPEZIL | 2013 |
|
RU2635528C2 |
| COMPOSITIONS AND METHODS OF PREVENTING AND TREATING ADDICTIONS | 2008 |
|
RU2492858C2 |
| NALMEFENE FOR REDUCTION OF ALCOHOL CONSUMPTION IN SPECIFIC TARGET POPULATIONS | 2013 |
|
RU2665373C2 |
| METHOD OF TREATING MAJOR DEPRESSION IN HUMAN | 2007 |
|
RU2445973C2 |
| VORTIOXYETINE PYROGLUTAMATE | 2016 |
|
RU2713889C2 |
| DIESTER NALMEFENE PRODRUGS | 2009 |
|
RU2495041C2 |
| PRODRUGS OF OPIOID RECEPTOR ANTAGONISTS | 2018 |
|
RU2785777C2 |
